Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
株式のランク #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
株価
$43.48
時価総額
$8.97B
変化(1日)
0.37%
変化(1年)
192.01%
US
取引 Immunovant, Inc. (IMVT)

カテゴリー

Immunovant, Inc.(IMVT)の配当履歴
Immunovant, Inc.(証券コード:IMVT)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのImmunovant, Inc.(IMVT)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH